Success Metrics

Clinical Success Rate
79.5%

Based on 1,967 completed trials

Completion Rate
79%(1967/2475)
Active Trials
351(11%)
Results Posted
64%(1252 trials)
Terminated
508(16%)

Phase Distribution

Ph phase_4
3
0%
Ph phase_3
148
5%
Ph early_phase_1
58
2%
Ph phase_1
995
32%
Ph phase_2
1,206
38%
Ph not_applicable
252
8%

Phase Distribution

1053

Early Stage

1206

Mid Stage

151

Late Stage

Phase Distribution2662 total trials
Early Phase 1First-in-human
58(2.2%)
Phase 1Safety & dosage
995(37.4%)
Phase 2Efficacy & side effects
1,206(45.3%)
Phase 3Large-scale testing
148(5.6%)
Phase 4Post-market surveillance
3(0.1%)
N/ANon-phased studies
252(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.3%

1967 of 2649 finished

Non-Completion Rate

25.7%

682 ended early

Currently Active

351

trials recruiting

Total Trials

3,144

all time

Status Distribution
Active(355)
Completed(1967)
Terminated(682)
Other(140)

Detailed Status

Completed1967
Terminated508
Active, not recruiting301
Withdrawn174
unknown128
Recruiting50

Development Timeline

Analytics

Development Status

Total Trials
3144
Active
351
Success Rate
79.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 158 (2.2%)
Phase 1995 (37.4%)
Phase 21206 (45.3%)
Phase 3148 (5.6%)
Phase 43 (0.1%)
N/A252 (9.5%)

Trials by Status

active_not_recruiting30110%
terminated50816%
suspended120%
not_yet_recruiting20%
unknown1284%
withdrawn1746%
completed196763%
recruiting502%
enrolling_by_invitation20%

Recent Activity

Clinical Trials (3,144)

Showing 20 of 3,144 trialsScroll for more
NCT02978625Phase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Active Not Recruiting
NCT01038778Phase 1

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Active Not Recruiting
NCT02227199Phase 1

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
NCT01267955Phase 2

Vismodegib in Treating Patients With Advanced Chondrosarcomas

Active Not Recruiting
NCT03409432Phase 2

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Completed
NCT03440567Phase 1

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Completed
NCT00770809Phase 3

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed
NCT01989585Phase 1

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active Not Recruiting
NCT02581930Phase 2

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Completed
NCT03220022Phase 1

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Active Not Recruiting
NCT03505762Phase 2

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Active Not Recruiting
NCT02756897Phase 2

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Active Not Recruiting
NCT02231775Phase 2

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Active Not Recruiting
NCT02955290Phase 1

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Active Not Recruiting
NCT02846623Phase 2

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Active Not Recruiting
NCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Recruiting
NCT00392353Phase 1

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Active Not Recruiting
NCT02455557Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT02311933Phase 2

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Active Not Recruiting
NCT01979523Phase 2

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Active Not Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
3,144